Scancell Holdings Plc Directorate Change (7732Q)
23 Ottobre 2019 - 8:00AM
UK Regulatory
TIDMSCLP
RNS Number : 7732Q
Scancell Holdings Plc
23 October 2019
23 October 2019
Scancell Holdings plc
("Scancell" or the "Company")
Directorate Change
Scancell Holdings plc, (AIM:SCLP), the developer of novel
immunotherapies for the treatment of cancer, is pleased to announce
the appointment of Dr Ursula Ney as a Non-Executive Director of the
Company with immediate effect, replacing Dr Matthew Frohn who is
standing down on 31 October 2019 after more than twelve years of
service to the Company.
Dr Ney has over thirty years' experience in the pharmaceutical
and biotechnology industry, including twenty years in senior
leadership roles that also encompassed Executive and Non-Executive
Board positions. She has broad experience of biologic and small
molecule drug development across a range of therapeutic areas
having been Director of Drug Development and on the Board of
Celltech plc and later Chief Operating Officer and Executive
Director of Antisoma plc. Most recently, she was Chief Executive
Officer of Genkyotex SA. She was on the Board of Discuva Ltd and is
currently also a Non-Executive Director of Proteome Sciences
plc.
Dr Ney's early career was spent at Sandoz (Switzerland) and
Roche (UK). She has a PhD from the Royal Free Hospital Medical
School and an MBA from Middlesex University Business School.
Commenting on the appointment, Dr John Chiplin Chairman of
Scancell, said:
"I am pleased to welcome Ursula to the Board of Scancell.
Ursula's extensive late stage development experience in the biotech
sector will be invaluable as the Company continues to develop its
product pipeline. I'd also like to take this opportunity to thank
Matthew Frohn for the invaluable contributions he has made to the
Company since he was first appointed to the Board in 2006. We wish
him well in his future endeavours."
Dr Ursula Ney commented:
"I am delighted to be joining the Scancell Board at this
exciting time and look forward to working with the team in
realising the potential of the ImmunoBody(R), Moditope(R) and
AvidiMab(TM) platforms."
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies
The following information is disclosed pursuant to Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies in
relation to Dr Ursula Mary Ney, aged 67:
Current Directorships Previous Directorships (last
5 years)
Proteome Sciences Genkyotex SA
University of Plymouth Discuva Limited
-----------------------------
As of the date of this announcement, Dr Ursula Ney holds no
ordinary shares in the capital of the Company.
Save as disclosed above there are no additional disclosures to
be made in accordance with Rule 17 or Schedule Two paragraph (g) of
the AIM Rules for Companies.
For Further Information:
Scancell Holdings plc
+44 (0) 20 3727
Dr John Chiplin, Chairman 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
+44 (0) 20 7886
Freddy Crossley/Emma Earl 2500
FTI Consulting +44 (0) 20 3727
Simon Conway/Natalie Garland-Collins 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They have the potential to be
used as monotherapy or in combination with checkpoint inhibitors
and other agents. This platform has the potential to enhance tumour
destruction, prevent disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK (CRUK) for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4 T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
AvidiMab(TM) is a patent protected technology platform which
increases the avidity of human antibodies by promoting non-covalent
Fc-Fc interactions. This modification induces the direct tumour
cell killing properties of Scancell's anti-glycan monoclonal
antibodies (mAbs) but has broad potential to increase the avidity
or potency of any therapeutic monoclonal antibody including those
being developed for autoimmune diseases, as well as cancer.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUUONRKSARUAA
(END) Dow Jones Newswires
October 23, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Apr 2023 a Apr 2024